scholarly journals DNA Binding of Jun and Fos bZip Domains: Homodimers and Heterodimers Induce a DNA Conformational Change in Solution

1996 ◽  
Vol 24 (22) ◽  
pp. 4487-4494 ◽  
Author(s):  
M. John ◽  
R. Leppik ◽  
S. J. Busch ◽  
M. Granger-Schnarr ◽  
M. Schnarr
2007 ◽  
Vol 282 (14) ◽  
pp. 10299-10310 ◽  
Author(s):  
Caterina Grillo ◽  
Chiara D'Ambrosio ◽  
Valerio Consalvi ◽  
Roberta Chiaraluce ◽  
Andrea Scaloni ◽  
...  

2000 ◽  
Vol 5 (6) ◽  
pp. 515-522 ◽  
Author(s):  
Jiro Usukura ◽  
Yuji Nishizawa ◽  
Atsushi Shimomura ◽  
Kazuto Kobayashi ◽  
Toshiharu Nagatsu ◽  
...  

2003 ◽  
Vol 23 (6) ◽  
pp. 1922-1934 ◽  
Author(s):  
Marcel J. M. Schaaf ◽  
John A. Cidlowski

ABSTRACT The actions of glucocorticoids are mediated by the glucocorticoid receptor (GR), which is activated upon ligand binding, and can alter the expression of target genes either by transrepression or transactivation. We have applied FRAP (fluorescence recovery after photobleaching) to quantitatively assess the mobility of the yellow fluorescent protein (YFP)-tagged human GR α-isoform (hGRα) in the nucleus of transiently transfected COS-1 cells and to elucidate determinants of its mobility. Addition of the high-affinity agonist dexamethasone markedly decreases the mobility of the receptor in a concentration-dependent manner, whereas low-affinity ligands like corticosterone decrease the mobility to a much lesser extent. Analysis of other hGRα ligands differing in affinity suggests that it is the affinity of the ligand that is a major determinant of the decrease in mobility. Similar results were observed for two hGRα antagonists, the low-affinity antagonist ZK98299 and the high-affinity antagonist RU486. The effect of ligand affinity on mobility was confirmed with the hGRα mutant Q642V, which has an altered affinity for triamcinolone acetonide, dexamethasone, and corticosterone. Analysis of hGRα deletion mutants indicates that both the DNA-binding domain and the ligand-binding domain of the receptor are required for a maximal ligand-induced decrease in receptor mobility. Interestingly, the mobility of transfected hGRα differs among cell types. Finally, the proteasome inhibitor MG132 immobilizes a subpopulation of unliganded receptors, via a mechanism requiring the DNA-binding domain and the N-terminal part of the ligand-binding domain. Ligand binding makes the GR resistant to the immobilizing effect of MG132, and this effect depends on the affinity of the ligand. Our data suggest that ligand binding induces a conformational change of the receptor which is dependent on the affinity of the ligand. This altered conformation decreases the mobility of the receptor, probably by targeting the receptor to relatively immobile nuclear domains with which it transiently associates. In addition, this conformational change blocks immobilization of the receptor by MG132.


2012 ◽  
Vol 134 (32) ◽  
pp. 13357-13365 ◽  
Author(s):  
Tatjana Heidebrecht ◽  
Alexander Fish ◽  
Eleonore von Castelmur ◽  
Kenneth A. Johnson ◽  
Giuseppe Zaccai ◽  
...  

2009 ◽  
Vol 37 (7) ◽  
pp. 2411-2417 ◽  
Author(s):  
U. de Silva ◽  
F. W. Perrino ◽  
T. Hollis

1998 ◽  
Vol 18 (8) ◽  
pp. 4639-4650 ◽  
Author(s):  
Sujatha Nagulapalli ◽  
Michael L. Atchison

ABSTRACT The transcription factors E2A (E12/E47) and Pip are both required for normal B-cell development. Each protein binds to regulatory sequences within various immunoglobulin enhancer elements. Activity of E2A proteins can be regulated by interactions with other proteins which influence their DNA binding or activation potential. Similarly, Pip function can be influenced by interaction with the protein PU.1, which can recruit Pip to bind to DNA. We show here that a previously unidentified Pip binding site resides adjacent to the E2A binding site within the immunoglobulin κ 3′ enhancer. Both of these binding sites are crucial for high-level enhancer activity. We found that E47 and Pip can functionally interact to generate a very potent 100-fold transcriptional synergy. Through a series of mutagenesis experiments, we identified the Pip sequences necessary for transcriptional activation and for synergy with E47. Two synergy domains (residues 140 to 207 and 300 to 420) in addition to the Pip DNA binding domain (residues 1 to 134) are required for maximal synergy with E47. We also identified a Pip domain (residues 207 to 300) that appears to mask Pip transactivation potential. Part of the synergy mechanism between E47 and Pip appears to involve the ability of Pip to increase DNA binding by E47, perhaps by inducing a conformational change in the E47 protein. E47 may also induce a conformational change in Pip which unmasks sequences important for transcriptional activity. Based upon our results, we propose a model for E47-Pip transcriptional synergy.


Sign in / Sign up

Export Citation Format

Share Document